ANKLE1: A Potential Drug Target and Biomarker (G126549)

Target Name: ANKLE1

NCBI ID: G126549

ANKLE1

ANKLE1: A Potential Drug Target and Biomarker

Ankyrin repeat domain-containing protein 41 (ANKLE1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ANKLE1 is a member of the superfamily of proteins known as the ankyrin repeats, which are characterized by the repeated sequence of the amino acid Asp-Glu-His. This family of proteins is known for their unique structure and the ability to form inclusion complexes with various small molecules, including drugs.

One of the unique features of ANKLE1 is its unique expression pattern. ANKLE1 is primarily expressed in the brain and central nervous system, but is also found in other tissues, including the heart, muscle, and blood vessels. This unique expression pattern makes ANKLE1 an attractive target for drugs that can modulate its expression and activity in these tissues.

In addition to its unique expression pattern, ANKLE1 has also been shown to play a role in several important cellular processes. For example, ANKLE1 has been shown to play a role in the regulation of ion channels, which are responsible for the flow of electrical signals through cells. This role is important for many different cellular processes, including muscle contractions, nerve signaling, and brain function.

Furthermore, ANKLE1 has also been shown to be involved in the regulation of cell adhesion. This process is important for the formation of tissues and organs and is also involved in the development of cancer. ANKLE1 has been shown to play a role in the regulation of cell adhesion by interacting with the protein cadherin, which is a transmembrane protein that is involved in cell-cell adhesion.

The potential drug targets for ANKLE1 are vast and varied. ANKLE1 has been shown to play a role in the regulation of ion channels, which are involved in many different cellular processes, including muscle contractions, nerve signaling, and brain function. This makes ANKLE1 an attractive target for drugs that can modulate its activity in these processes. Additionally, ANKLE1 has also been shown to play a role in the regulation of cell adhesion, which is important for the formation of tissues and organs and is also involved in the development of cancer.

Ankyrin repeat domain-containing protein 41 (ANKLE1) has also been shown to play a role in the regulation of many different signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and inflammation. ANKLE1 has been shown to play a role in the regulation of TGF-β signaling by interacting with the protein Smad2, which is a key regulator of TGF-β signaling.

In conclusion, ANKLE1 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique expression pattern and involvement in several important cellular processes make ANKLE1 an attractive target for drugs that can modulate its activity in these tissues. Further research is needed to fully understand the role of ANKLE1 in disease and to develop effective treatments.

Protein Name: Ankyrin Repeat And LEM Domain Containing 1

Functions: Endonuclease that probably plays a role in the DNA damage response and DNA repair

The "ANKLE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKLE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets